Vitespen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Vitespen
DrugBank Accession Number
DB06400
Background

Not Available

Type
Biotech
Groups
Investigational
Biologic Classification
Vaccines
Other vaccines
Synonyms
  • Endoplasmin (human tumor rejection antigen 1)
  • Heat shock protein-peptide complex-96 vaccine
  • Oncophage
  • Vitespen
External IDs
  • HSPPC 96
  • HSPPC-96
  • HSPPC96

Pharmacology

Indication

Investigated for use/treatment in kidney cancer, melanoma, renal cell carcinoma, lymphoma (unspecified), colorectal cancer, and brain cancer.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action

HSPPC-96 is a protein peptide complex consisting of a 96 kDa heat shock protein (Hsp), gp96, and an array of gp96-associated cellular peptides. Immunisation with HSPPC-96 induces T-cell specific immunity against these peptides; gp96 is not immunogenic per se. The non-covalent binding of gp96 to peptides is neither selective nor restricted to cell types. Thus, the collection of gp96-associated peptides represents the antigenic peptide pool of a cell; this is the basis of the peptide-specific immunogenicity elicited by HSPPC-96.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe therapeutic efficacy of Vitespen can be decreased when used in combination with Abatacept.
AdalimumabThe therapeutic efficacy of Vitespen can be decreased when used in combination with Adalimumab.
AldesleukinThe therapeutic efficacy of Vitespen can be decreased when used in combination with Aldesleukin.
AlefaceptThe therapeutic efficacy of Vitespen can be decreased when used in combination with Alefacept.
AlemtuzumabThe therapeutic efficacy of Vitespen can be decreased when used in combination with Alemtuzumab.
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
H3598Y1TLJ
CAS number
492448-75-6

References

General References
  1. Minev BR: Technology evaluation: HSPPC-96, antigenics. Curr Opin Mol Ther. 2003 Dec;5(6):680-7. [Article]
  2. Caudill MM, Li Z: HSPPC-96: a personalised cancer vaccine. Expert Opin Biol Ther. 2001 May;1(3):539-47. [Article]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentMalignant Melanoma1
3CompletedTreatmentRenal Cell Carcinoma (RCC)1
3TerminatedTreatmentRenal Cancer / Renal Cell Carcinoma (RCC)1
2CompletedNot AvailableLung Cancer / Non-Small Cell Lung Carcinoma1
2CompletedTreatmentBrain and Central Nervous System Tumors1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Drug created at March 19, 2008 16:29 / Updated at September 19, 2023 04:36